It is made available under a CC-BY-NC-ND 4.0 International license .

1	Identification of rare loss of function variation regulating body fat distribution						
2	Authors: Mine Koprulu ^{a#} , Yajie Zhao ^{a#} , Eleanor Wheeler ^a , Liang Dong ^b , Nuno Rocha ^b , Satish Patel ^b ,						
3	Marcel Van de Streek ^c , Craig A. Glastonbury ^d , Isobel D. Stewart ^a , Felix R. Day ^a , Jian'an Luan ^a ,						
4	Nicholas Bowker ^a , Laura B. L. Wittemans ^a , Nicola D. Kerrison ^a , Debora M. E. Lucarelli ^a , Inês Barroso ^e ,						
5	Mark I. McCarthy ^f , Robert A. Scott ^a , Vladimir Saudek ^b , Kerrin S. Small ^c , Nicholas J. Wareham ^a ,						
6	Robert K. Semple ^g , John R. B. Perry ^a , Stephen O'Rahilly ^b , Luca A. Lotta ^a , Claudia Langenberg ^{a,h*} ,						
7	David B. Savage ^b *						
8 9 10	a.	MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Box 285 Institute of Metabolic Science, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0QQ					
11 12 13	b.	University of Cambridge Metabolic Research Laboratories, Wellcome Trust-MRC Institute of Metabolic Science, Box 289, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0 QQ					
14	c.	Department of Twin Research and Genetic Epidemiology, King's College London, St Thomas'					
15		Campus, Lambeth Palace Road, London, SE1 7EH, United Kingdom					
16	d.	BenevolentAI Limited, 4-8 Maple St, London W1T 5HD					
17	e.	Wellcome Sanger Institute, Hinxton, Cambridge, CB10 1SA, United Kingdom					
18	f.	Wellcome Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford, OX3					
19		7BN, United Kingdom					
20	g.	Centre for Cardiovascular Science, University of Edinburgh, 47 Little France Crescent,					
21		Edinburgh, EH16 4TJ, UK					
22	h.	Computational Medicine, Berlin Institute of Health at Charité – Universitätsmedizin Berlin,					
23		Germany					
24							
25	# authors contributed equally						
26	* authors contributed equally						
27							
28	Correspondence to:						
29	Claudia Langenberg (claudia.langenberg@mrc-epid.cam.ac.uk)						
30	David B. Savage (dbs23@medschl.cam.ac.uk)						

31

It is made available under a CC-BY-NC-ND 4.0 International license .

32 ABSTRACT

33 Biological and translational insights from large-scale, array-based genetic studies of fat distribution, a key 34 determinant of metabolic health, have been limited by the difficulty in linking identified predominantly 35 non-coding variants to specific gene targets. Rare coding variant analyses provide greater confidence that 36 a specific gene is involved, but do not necessarily indicate whether gain or loss of function would be of 37 most therapeutic benefit. Here we use a dual approach that combines the power of genome-wide analysis 38 of array-based rare, non-synonymous variants in 184,246 individuals of UK Biobank with exome-sequence-39 based rare loss of function gene burden testing. The data indicates that loss-of-function (LoF) of four genes 40 (PLIN1, INSR, ACVR1C and PDE3B) is associated with a beneficial impact on WHR_{adiBMI} and increased gluteofemoral fat mass, whereas PLIN4 LoF adversely affects these parameters. This study robustly 41 42 implicates these genes in the regulation of fat distribution, providing new and in some cases somewhat 43 counter-intuitive insight into the potential consequences of targeting these molecules therapeutically. 44

45 Word count: 161

It is made available under a CC-BY-NC-ND 4.0 International license .

46 INTRODUCTION

47 Fat distribution is a heritable trait, commonly estimated by the relative amounts of waist and hip fat (waistto-hip ratio, WHR) for a given body size. Genetic mechanisms linked to either relatively lower 48 49 gluteofemoral or higher abdominal fat or both, have been shown to contribute to a greater WHR and its 50 consistently adverse cardiometabolic consequences (1). Genome-wide array-based association studies have 51 robustly identified many loci linked to WHR but thus far provided relatively limited biological and 52 translational insights due to poor coverage of rare protein-coding variants and uncertainties connecting 53 associated non-coding variants to functional genes (2, 3). Consequently, very few genes have been 54 definitively linked to WHR and it is generally unknown whether a gain or loss of gene function is likely to 55 drive observed associations.

56 The low frequency of rare (minor allele frequency [MAF] <0.5%, as defined by the 1000 Genomes Project 57 (4)) functional variants which may have sizable effects on the encoded protein, may be a consequence of 58 selective pressure acting against them, and previous studies have shown inverse relationships between 59 allele frequency and effect size for complex traits (5, 6). Rare variants that occurred recently are also likely 60 to be in low linkage disequilibrium (LD) with nearby common variants, facilitating fine-mapping and 61 identification of causal variants and genes (7). However, rare variants are difficult to impute (8) so their 62 study requires large, homogeneous samples and direct genotyping. To date, the vast majority of studies 63 have explored the contribution of common variants in relation to WHR including the largest meta-analysis 64 of imputed genome-wide association studies which included up to 694,649 individuals but only identified two variants at MAF 0.1-0.5% (3). The only other study which investigated the role of rare variants for 65 WHR was a subsequent trans-ethnic Exomechip effort that identified 9 low frequency or rare variants with 66 67 a lowest MAF of 0.1% (9).

68 The contribution of the full spectrum of rare variants to WHR using sequence data has not been studied, 69 yet has the potential to provide a more direct link between gene and phenotype, and to facilitate translation 70 from gene identification to drug development. Whilst the identification of coding variants in a specific gene 71 clearly increases confidence in linking that particular gene to a trait, the impact of individual coding variants 72 can still be very, or at least relatively, subtle. Individual variant testing, even using exome sequencing data 73 in large populations, therefore still provides limited power and leaves residual uncertainty about the benefits of gain or loss of function of a particular gene. Exome wide scans of gene-based burden of rare loss-of-74 function variants have the potential to address this limitation (10-14). In this study, we use a dual approach 75 76 that combines the power of large-scale genome-wide analysis of array-based rare, non-synonymous variants 77 with exome-sequence-based rare gene burden testing to identify the putative function of variants, genes and

It is made available under a CC-BY-NC-ND 4.0 International license .

- 78 pathways regulating body shape and fat distribution (assessed by BMI-adjusted WHR [WHR_{adjBMI}]) and to
- 79 determine their effects on body composition and metabolic health.

80 **RESULTS**


81 A genome-wide analysis of directly genotyped, rare $(0.1\% \leq MAF \leq 0.5\%)$ non-synonymous variants associated with WHR_{adjBMI} at $p < 5 \times 10^{-8}$ in 450,562 European ancestry individuals from UK Biobank 82 identified lead variants in PLIN1 p.L90P (rs139271800, EAF=0.1%), PDE3B p.R783X (rs150090666, 83 EAF=0.1%), ACVR1C p.I195T (rs56188432, EAF=0.2%), CALCRL p.L87P (rs61739909; EAF=0.3%), 84 85 ABHD15 p.G147D (rs141385558; EAF=0.2%) and PYGM p.R50X (rs116987552, EAF=0.4%) (Figure 1, 86 Supplementary Table 1). We observed a correlation of 0.99 and minor allele concordance of 0.99 comparing 87 genotyped to whole-exome sequenced rare $(0.1 \le MAF \le 0.5\%)$ non-synonymous variants when testing the 88 validity of rare, genotyped variants using exome-sequencing data from the overlapping samples

89 (Supplementary Table 2).

90 Sex-differences in genetic effects of rare variants on WHR_{adjBMI}

Common variant analyses have provided evidence of differences in genetic associations with fat distribution between men and women (3). In line with this, we found evidence of significant sex interactions, with stronger genetic effects in women, compared to men for all lead variants, except for *ACVR1C* p.I195T and *PYGM* p.R50X (Table 1). We therefore conducted sex-specific analyses which revealed two additional variants, *PLCB3* p.V806I (rs145502455, EAF=0.4%) and *FNIP1* p.R518Q (rs115209326, EAF=0.3%) to be genome-significant in ($p < 5 \times 10^{-8}$) in women, with no effect in men (Table 1, Supplementary Table 1). No variants reached genome-wide significance in men only.

It is made available under a CC-BY-NC-ND 4.0 International license .



98

Figure 1. Miami plot for sex-combined and sex-specific single marker association results for WHR_{adjBMI}. *Top*: Manhattan plot representing results from the main, sex-combined GWAS for WHR_{adjBMI} for genotyped, rare nonsynonymous variants ($0.1\% \le MAF \le 0.5\%$, correlation and rare allele concordance >0.9 when compared to the exome sequencing data). Gene annotations for the genome-wide significant variants from the main, sex-combined analyses are shown in black; gene annotations and significance from the main, sex-combined analyses for variants that were genome-wide significant in sex-specific analyses (women) only are shown in red. *Bottom*: Sex-specific significance of the variants highlighted above.

106

Variant	rsID	Sex interaction <i>p</i> value	p value Women	p value Men	Beta Women	Beta Men	SE Women	SE Men
PLIN1 p.L90P	rs139271800	4.07×10 ⁻³	1.90×10 ⁻¹³	4.50×10 ⁻³	-0.273	-0.126	0.039	0.042
<i>PDE3B</i> p.R783X	rs150090666	5.66×10-5	1.00×10 ⁻¹⁹	4.10×10 ⁻²	-0.392	-0.102	0.042	0.048
ACVR1C p.I195T	rs56188432	3.61×10 ⁻¹	1.10×10 ⁻⁸	3.40×10 ⁻⁴	-0.16	-0.109	0.028	0.032
CALCRL p.L87P	rs61739909	4.30×10 ⁻³	4.30×10 ⁻¹³	2.50×10 ⁻³	-0.171	-0.082	0.024	0.026
<i>ABHD15</i> p.G147D	rs141385558	4.53×10 ⁻³	3.40×10 ⁻¹⁰	3.80×10 ⁻²	0.168	0.057	0.026	0.029
PYGM p.R50X	rs116987552	3.56×10 ⁻¹	2.90×10 ⁻⁴	5.40×10 ⁻⁵	0.079	0.095	0.021	0.024
<i>PLCB3</i> p.V806I	rs145502455	2.34×10 ⁻²	1.60×10 ⁻¹⁰	2.00×10 ⁻¹	0.126	0.029	0.021	0.024
<i>FNIP1</i> p.R518Q	rs115209326	6.09×10 ⁻⁴	4.80×10 ⁻⁹	8.40×10 ⁻¹	-0.128	-0.003	0.023	0.026

107 Table 1: Sex-stratified results for variants identified in joint and sex specific analyses of genotyped rare variants

108 in UK Biobank. Unshaded rows present results discovered from the sex-combined analysis and grey shaded rows

109 represent results from variants identified only in the sex-stratified (women) analysis. Abbreviations: p value Women,

It is made available under a CC-BY-NC-ND 4.0 International license .

BOLT LMM p-value in women; p value Men, BOLT LMM p-value in men; Beta Women, effect size in women; Beta
 Men, effect size in men; SE Women, standard error in women; SE Men, standard error in men.

112 Genomic context and fine-mapping analyses

We found strong statistical evidence for causal associations of rare non-synonymous variants in *PLIN1*, 113 PDE3B, ACVR1C and CALCRL (Supplementary Note 1, Supplementary Table 3, Supplementary Figure 1) 114 through conditional analysis and fine-mapping, whereas genomic context analyses did not support the 115 causality of the identified rare lead variants in ABHD15 or PYGM from the joint (sex-combined) analysis, 116 117 and of *PLCB3* and *FNIP1* in the women-only analysis (Supplementary Note 2, Supplementary Table 4). 118 Bioinformatic analysis of these variants strongly predicted that the PDE3B variant p.R783X would truncate PDE3B within the catalytic site, impairing PDE3B catalytic activity if expressed (Supplementary Note 3), 119 120 whereas predictions of the functional impact of the PLIN1, ACVR1C and CALCRL variants were less 121 conclusive (Supplementary Note 3).


122 Exome-sequenced based burden testing of rare, loss-of function variants

123 Next, we considered the genes identified in the single variant analysis for exome-sequence-based gene rare 124 LoF and missense burden testing in 184,246 individuals in UK Biobank (see Methods, Gene-based 125 association testing) and found that *PLIN1*, *PDE3B*, *ACVR1C*, and *CALCRL* were all significantly associated 126 with lower WHR_{adjBMI} at a Bonferroni corrected threshold (p<0.0125). Predicted loss of function (pLoF) 127 variants showed the most significant association for *PLIN1* and *PDE3B*, moderate impact variants for 128 *CALCRL*, and the combination of pLoF with moderate impact variants for *ACVR1C* (Supplementary Table 129 5).

In order to identify additional genes where loss of function may regulate fat distribution, we extended this approach to a hypothesis free, exome-wide analysis ($p < 2.53 \times 10^{-6}$) for WHR_{adjBMI} using more stringent quality control (QC) parameters (see Methods). This identified *PLIN4* and *INSR* in at least one of the variant categories (see Methods), in addition to *PLIN1, ACVR1C* and *PDE3B* (Figure 2, Supplementary Table 6). *PLIN4, INSR* and *PDE3B* all showed significantly larger standardized effect sizes for women compared to

135 men (p < 0.05) in gene-based analyses, in line with the single marker results (Supplementary Table 7).

It is made available under a CC-BY-NC-ND 4.0 International license .



137Figure 2. Gene-based association results. Gene-based exome-wide discovery results for WHR_{adjBMI}. The horizontal138dashed line represents the exome-wide significance threshold ($p=2.53\times10^{-6}$).


139

140 While the joint effect of rare LoF variants in *PLIN4* (65 variants, 1,065 carriers) was associated with a higher WHR_{adiBMI} (Beta = 0.16 [0.10 – 0.22], $p=5.86\times10^{-7}$), the combination of rare LoF variants in *PLIN1* 141 (31 variants, 393 carriers) was associated with a lower WHR_{adjBMI}, (Beta = -0.27 [-0.17 - -0.36], $p=9.82\times10^{-1}$ 142 ⁹) (Supplementary Table 6). The lead *PLIN1* LoF variant (*PLIN1* p.T338DfsX51, rs750619494) is predicted 143 144 to result in a frameshift from amino acid 338 with a premature stop at amino acid 388, though it may well 145 be subject to nonsense mediated RNA decay. Several additional PLIN1 variants are similarly expected to result in early truncations or nonsense mediated RNA decay (Supplementary Table 8). In either instance, 146 these variants are expected to impair Plin1 interaction with ABHD5 and thus it's regulation of adipose 147 triglyceride lipase (ATGL) (15). In the case of PLIN4 (p.Q372X, rs201581703), the variant list also included 148 149 early frameshift/premature stop variants predicted to result in nonsense mediated RNA decay.

150 We next assessed phenotypic associations with refined measures of fat distribution and cardiometabolic 151 parameters and diseases. Bioelectrical Impedance Analysis (BIA) derived body fat compartment 152 measurements (16) showed that PLIN4 (pLoF) was associated with higher android and trunk fat, and lower 153 gynoid and leg fat (Figure 3, Supplementary Figure 2, Supplementary Table 9) whereas PLIN1 (pLoF) acted in the opposite direction. Fat distribution is strongly linked to insulin resistance, but as direct 154 155 indicators of insulin resistance are not currently available in UK Biobank, we evaluated the impact of these genes on metabolic indicators typically associated with insulin resistance (17, 18) (Figure 3, Supplementary 156 Figure 2, Supplementary Table 9). PLIN4 LoF was associated with higher triglycerides (TGs), TG/HDL 157 158 (triglyceride/high-density lipoprotein cholesterol) ratio and higher HbA1c levels. The associations for 159 PLIN1 consistently contrasted with those of PLIN4 with lower TGs, TG/HDL ratio and additionally higher

It is made available under a CC-BY-NC-ND 4.0 International license .

160 HDL cholesterol levels, in keeping with a beneficial impact on insulin sensitivity. In keeping with these 161 findings, *PLIN4* LoF was nominally associated with an increased risk for type 2 diabetes (T2D) (OR=1.36 [1.06-1.66], p=0.04) in the Type 2 Diabetes Knowledge Portal (T2DKP; https://t2d.hugeamp.org/), though 162 none of the genes showed a significant association with T2D in UK Biobank through our analysis or in the 163 AstraZeneca PheWAS Portal (https://azphewas.com/) (Supplementary Figure 2; Supplementary Table 9; 164 Supplementary Table 10). PLINI LoF showed nominal significance for a lower risk of cardiovascular heart 165 disease (CHD) (p=0.03, OR=0.55[0.31-0.91]) in our analysis of UK Biobank, a finding supported by 166 167 association between PLIN1 LoF and reduced susceptibility to chronic ischemic heart disease (OR=0.40 [0.32-0.75], $p=4.49\times10^{-4}$) in the AstraZeneca PheWAS Portal (14). 168



169


- Figure 3. Forest plot of phenotypic associations for significant variant-gene categories. Black represents the sexcombined, blue represents the men-only and red represents the women-only analysis. Horizontal lines represent 95%
 confidence intervals. Waist-to-hip ratio adjusted for BMI (n=184,246), gynoid fat adjusted for total body fat (n=
 178,143), trunk fat adjusted for total body fat (178,143), triglyceride levels (n=175,271) and HDL cholesterol
 (n=161,239) were all driven from UK Biobank (See Supplementary Table 12 for details).
- Similarly to *PLIN1*, the combined effect of LoF variants in the *INSR* (27 variants, 61 carriers) was associated with lower WHR_{adjBMI} (Beta=-0.64[-0.39 - -0.88], $p=6.21\times10^{-7}$; Supplementary Table 6). Although a few common intronic variants (rs1035942, rs1035940, rs62124511, rs34194998) and a low-

It is made available under a CC-BY-NC-ND 4.0 International license .

178 frequency synonymous variant (rs1799815) in the *INSR* have previously been associated with WHR_{adiBMI} 179 (3, 19), the causal mechanism underlying these associations remains unknown. Our gene-based findings 180 indicate that the *INSR* can alter body fat distribution through loss of function. Given the fact that the *INSR* gene encodes the insulin receptor itself and that both biallelic and heterozygous loss of function variants in 181 182 this gene have long been linked with monogenic severe insulin resistance syndromes (20), this evidence for loss of function of the *INSR* having a seemingly beneficial effect on fat distribution i.e. lower WHR_{adiBMI} is 183 184 surprising. Importantly, none of the *INSR* mutations previously linked to monogenic disease were present 185 in our UK Biobank analysis. The lead *INSR* variant (p.R525X) is predicted to result in truncation of the 186 protein within the extracellular domain preventing interaction of the extra- and intra-cellular domains, and 187 thus formation of a functional receptor. In the homozygous state, this would be expected to lead to 188 monogenic severe insulin resistance. In terms of body fat distribution, heterozygous INSR LoF was also 189 associated with higher gynoid and leg fat, and lower android and trunk fat mass (Figure 3, Supplementary Figure 2, Supplementary Table 9). Similarly to the cardio-metabolic associations of *PLIN1* indicating a 190 191 beneficial effect, heterozygous loss of INSR was associated with lower TGs and a lower TG/HDL ratio 192 (Figure 3, Supplementary Figure 2, Supplementary Table 9). It was also associated with lower LDL (low-193 density lipoprotein) cholesterol levels but was not associated with altered HDL (Figure 3, Supplementary 194 Figure 2, Supplementary Table 9). Despite these seemingly favourable changes in fat distribution and 195 plasma lipids, *INSR* LoF showed a nominal association for increased susceptibility to T2D in the T2DKP 196 (OR=3.67[2.50-4.83], *p*=0.02) (Supplementary Table 10).

197 For ACVR1C, the genetic architecture of gene-based results was slightly different, gene-based association 198 results were significant for (i) the combined burden of pLoF and moderate impact variants and (ii) for moderate impact variants only. There were 130 rare moderate impact variants and 9 rare high impact 199 200 variants included in this analysis [1414 and 16 carriers, respectively]. The combined effect of pLoF and 201 moderate impact variants and moderate impact only variants were both associated with lower WHR_{adiBMI} (Beta=-0.15 [-0.10 - -0.20] and -0.15[-0.10 - -0.20], $p=1.68\times10^{-7}$ and 4.57×10^{-7} , respectively; 202 203 Supplementary Table 6). In this instance, the highest-ranking variant was the previously reported p.I195T 204 variant (19, 21). In silico predictions including M-CAP (22), REVEL (23), SIFT (24), PolyPhen-2 (25) and 205 PROVEAN (26) all asses this variant to be damaging to the protein and structural modelling also suggests 206 that it is likely to have a sizable impact (Supplementary Note 3). CADD (27) also estimates this variant to 207 be among the top 1% of the deleterious variants ranked by CADD (score = 27.1). To test this prediction, 208 we performed a luciferase reporter assay in HEK293 cells which strongly suggested that the mutation 209 impairs ACVR1C signalling (Figure 4).

It is made available under a CC-BY-NC-ND 4.0 International license .



210 211

212 Figure 4. Functional impact of ACVR1C I195T variant on Smad signalling. HEK293 cells were transiently 213 transfected with ACVR1C expression constructs and their receptor components, along with firefly and Renilla 214 luciferase expression plasmids. Firefly luciferase activity was normalised to *Renilla* activity and the luciferase 215 activity in non-stimulated cells transfected with empty vector (EV) was set to 1. A constitutively active (CA) 216 ACVR1C variant T194D and a kinase dead (KD) variant K222R were included for comparison. Results from 217 three independent experiments are presented as mean \pm SD. Statistical significance was evaluated by one-way 218 ANOVA with Tukey's post hoc test for multiple comparisons between pairs. WT, wild type ACVR1C. * P <219 0.001, ns not significant.

220

The phenotypic associations for *ACVR1C* LoF for fat categories were similar to *PLIN1* LoF, with significant associations with higher gynoid and leg fat, and lower android and trunk fat. However, the cardio-metabolic associations were less clear for *ACVR1C* with an association with lower TG and but not HDL or the TG/HDL ratio (Figure 3, Supplementary Figure 2; Supplementary Table 9).

225

226 Finally, the combined effect of LoF variants in *PDE3B* was also significantly associated with lower 227 WHR_{adiBMI}. However, leave-one-out analysis suggested that this association was mainly driven by the 228 premature stop variant (p.R783X, rs150090666; p-value after dropping the variant=0.49; Supplementary 229 Table 11). All other candidate genes remained at least nominally significant after dropping the most 230 significant variant (Supplementary Table 11). Our analysis of the PDE3B p.R783X variant was in line with 231 previous reports associating it with lower triglyceride levels and higher HDL (28, 29). PDE3B p.R783X 232 has also been reported to be associated with higher apolipoprotein B, lower apolipoprotein A1 levels and 233 other haematological traits (30). This variant was reported to be significantly associated with cardiovascular 234 disease when meta-analysed in UK Biobank and other cohorts (29, 31). 235

- 236
- ____
- 237

It is made available under a CC-BY-NC-ND 4.0 International license .

238 DISCUSSION

Central adiposity has long been linked to insulin resistance and metabolic disease (32-37) but exactly why 239 240 this is the case and, other than sex hormones, what exactly determines fat distribution remains incompletely 241 understood. So, what have we learnt from human genetics thus far? Firstly, that inheritance contributes to 242 WHR (3, 38). Secondly, monogenic partial lipodystrophies indicate that single gene variants can be 243 sufficient to mediate substantial changes in fat distribution, classic examples being mutations in LMNA and 244 *PPARG.* Interestingly, both proteins are expressed in all white adipocytes and yet specific loss of function 245 variants are consistently associated with loss of hip and leg fat whereas visceral fat is preserved (39). 246 Thirdly, whilst the beneficial impact of thiazolidinediones, one of very few drugs that clearly improve 247 insulin sensitivity, was recognised before the discovery of PPARG mutations in patients with partial lipodystrophy, this link attests to the potential for human genetics to inform drug discovery. Fourthly, 248 249 GWAS studies have identified many loci associated with WHR (2, 3, 9) though these have yet to be 250 translated into therapeutic targets. Finally, Mendelian Randomization has been used to establish that genetic 251 mechanisms linked to greater WHR_{adiBMI} can be causally linked to the risk of cardiovascular disease and 252 type 2 diabetes through either relatively *lower* gluteofemoral or *higher* abdominal fat or both (40). 253 Furthermore, these associations are very likely to be underpinned by insulin resistance as the genetic risk 254 score for WHR_{adiBMI} was also shown to be strongly associated with elevated fasting insulin, higher 255 triglycerides and lower HDL cholesterol (40).

256 Our WHR_{adiBMI} single variant analysis in samples from 450,562 UK Biobank participants revealed missense 257 variants in 3 genes (CALCRL, PLIN1 and ACVR1C) and a nonsense variant in PDE3B. All these genes are 258 highly expressed in adipose tissue in keeping with emerging evidence that adiposity itself is largely centrally mediated whereas where excess energy is stored is regulated within adipose tissue itself (2, 41). 259 260 CALCRL is also expressed in a host of other tissues and its role in adipose tissue remains to be established 261 (42, 43). *PLIN1* is a lipid droplet surface protein almost exclusively expressed in adjocytes and has a well-262 established role in regulating both triglyceride and diacylglycerol hydrolysis (44). PDE3B is expressed in 263 many tissues but has long been linked to adipocyte lipolysis, and specifically to insulin mediated inhibition 264 of lipolysis (45, 46). Several lines of evidence have recently implicated ACVR1C in the regulation of 265 lipolysis, but it is expressed in many tissues in addition to adipose tissue and further work is required to 266 convincingly establish exactly what it does in adipocytes (47-49).

In terms of the impact of the specific mutations present in each gene, the *PDE3B* p.R783X is clearly
expected to impair *PDE3B* catalytic activity, and thus potentially to increase cAMP levels and lipolysis,
but the impact of the other three variants is far less certain (see Supplementary Note 3). Interestingly, gene

270 based LoF burden analyses for all four genes were at least nominally significant, suggesting that the single

It is made available under a CC-BY-NC-ND 4.0 International license .

variants were most likely to impair function of the encoded proteins. At least when transiently transfected
into cultured cells, our functional data is also consistent with the LoF predictions for the *ACVR1C* p.I195T
variant.

274 Our exome wide analyses confirmed significant effects of LoF variants in PLIN1, ACVR1C and PDE3B. In 275 the cases of ACVR1C and PDE3B, the lead LoF variants were the same as single variants reported above, 276 namely the ACVR1C p.I195T and PDE3B p.R783X variants. The fact that the phenotypic associations of 277 the *PLIN1* p.L90P variant are directionally consistent with the *PLIN1* LoF gene burden data suggests that 278 this variant is likely to be a loss of function variant too. Both the lead PLIN1 variant and several additional 279 PLINI variants are expected to result in early truncations or nonsense mediated RNA decay. These data are 280 consistent with Laver et al.'s assertion that PLIN1 haploinsufficiency is not associated with lipodystrophy 281 (50). Interestingly, several heterozygous *PLIN1* frameshift variants had previously been linked to partial 282 lipodystrophy (51). None of these variants overlap with those identified in UK Biobank to date and none 283 are predicted to result in nonsense mediated RNA decay. Instead, in several cases, immunoblotting of 284 adipose tissue lysates confirmed expression of an elongated form of Perilipin 1 in addition to the wildtype 285 copy, so perhaps expression of these mutant forms with an altered carboxy-terminus, accounts for the 286 seemingly 'opposite' phenotypes (51, 52).

Gene burden testing also highlighted the role of *PLIN4* LoF variants in fat distribution, though in this case, these had an adverse impact on WHR_{adjBMI}. Whilst a higher WHR_{adjBMI} would conventionally be deemed to be metabolically adverse, it is possible that this need not be the case for all genetic perturbations, however, our phenotypic analyses were consistent with the predicted outcomes for all the above genes, in fact, the phenotypic associations for *PLIN1* and *PLIN4* were consistently opposite. Similar to *PLIN1*, *PLIN4* is highly expressed in adipose tissue, but it is also expressed in heart and skeletal muscle, and the *PLIN4* knockout mouse has not been reported to have an adipose tissue phenotype to date (53).

294 The last gene identified in the exome wide gene burden analysis was the *INSR*. In this instance, the lead 295 variant (p.R525X) is expected to truncate the protein in the alpha subunit shortly before the disulphide bond 296 normally connecting alpha and beta subunits. This is expected to abrogate synthesis of functional receptor. 297 Even if truncated protein were synthesised this would not be able to dimerise with or exert dominant 298 negative activity over co-expressed wild type receptor, and so heterozygosity for the truncating variant 299 would be expected to reduce functional receptor protein by \sim 50%. In keeping with this, biallelic mutations 300 in this domain usually cause extreme IR classified as Donohue or Rabson-Mendenhall syndrome. Parents 301 of affected children have not been systematically studied and are generally held to be metabolically normal. 302 In contrast, heterozygous INSR variants in the intracellular beta subunit, which are synthesised and interfere

It is made available under a CC-BY-NC-ND 4.0 International license .

303 with wild type receptor function, cause type A insulin resistance (20). Whilst fat mass is often reduced in 304 Donohue's syndrome, heterozygous variants associated with type A insulin resistance are not reported to 305 be associated with fat redistribution and interestingly do not typically lead to fatty liver or dyslipidaemia (20). Our data suggest, surprisingly, that the *INSR* LoF variants favourably impact WHR_{adiBMI} and LDL 306 307 cholesterol. Whilst the INSR LoF association with T2D was relatively weak statistically and not seen in all 308 the cohorts assessed, it is conceivable that *INSR* LoF might adversely affect pancreatic beta cell function 309 and/or insulin sensitivity despite the apparently beneficial impact on fat distribution. The change in 310 triglycerides is somewhat reminiscent of the well described absence of dyslipidaemia in patients with 311 monogenic severe insulin resistance due to bi- or mono-allelic INSR mutations, so again this does not 312 preclude the INSR LOF variants being associated with reduced insulin sensitivity.

313 Our sex-specific analyses consistently revealed stronger effects in women than in men. These data are 314 consistent with the fact that WHR is more strongly associated with insulin resistance in women than in men 315 (54). Fat mass in women is consistently significantly higher than men of a similar BMI, who typically have 316 higher lean/muscle mass. The adverse impact of a lack of lower limb/gluteofemoral fat on metabolism is 317 strikingly apparent in patients with familial partial lipodystrophy, particularly types 2 and 3, due to specific 318 mutations in LMNA and PPARG respectively (39). In these and in fact in all forms of partial lipodystrophy, 319 metabolic disease manifests considerably earlier and is typically more severe in women than in men (39, 320 55, 56).

321 Our analyses have several limitations which future work should help to resolve. Firstly, the statistical power 322 to detect associations, particularly when examining rare variants, depends on the sample size. Hence, there 323 is the opportunity to discover additional findings when the WES data is released in the full UK Biobank 324 cohort or other large-scale studies. Secondly, the phenotypic follow up of cardiometabolic diseases for the 325 candidate genes was primarily conducted in UK Biobank, a population cohort with a limited number of 326 cases of specific diseases. Our follow-up in T2DKP revealed the potential of datasets enriched for cases to increase statistical power in phenotypic follow ups. Thirdly, fat distribution is strongly associated with 327 328 insulin resistance, but the UK Biobank cohort did not provide fasting samples so direct measures of insulin 329 and inferred indices of insulin sensitivity are not available.

In conclusion, our analysis strongly implicates at least four genes in the regulation of fat distribution. Furthermore, the data suggests that inhibitors of *PLIN1*, *PDE3B* and *ACVR1C* might favourably impact fat distribution and associated metabolic phenotypes whereas *PLIN4* inhibition is likely to have adverse health consequences. The data in *PLIN1* needs to be tempered by the earlier reports linking some specific *PLIN1* LoF variants with partial lipodystrophy. Finally, the data on the *INSR* seemed to suggest a potential disconnect between an apparently favourable impact of LoF variants on WHR and an apparently adverse

It is made available under a CC-BY-NC-ND 4.0 International license .

- impact on T2D risk. These findings provide valuable insight into the potential of these genes as therapeutic
- 337 targets.

338

It is made available under a CC-BY-NC-ND 4.0 International license .

339 METHODS

340

341 The UK Biobank Resource

342 The UK Biobank is a large-scale prospective population-based study of approximately 500,000 participants 343 aged 40-69 at the time of recruitment (57). Recruitment took place between 2006-2010 in centres across 344 the United Kingdom and participants have deep phenotypic information collected from initial and repeat 345 assessment visits, health records, self-reported survey information, linkage to death and cancer registries, 346 urine and blood biomarkers and other phenotypic endpoints. A Seca 200 cm tape was used to measure waist and hip circumference at the baseline visit, and BMI was calculated from height and weight 347 348 measurements. WHR_{adjBMI} was constructed as the ratio of waist and hip circumferences adjusted for age, 349 age² and BMI (measured at the baseline assessment visit). Residuals were calculated for men and women 350 separately and then transformed using the rank-based inverse normal transformation. All additional 351 phenotypes are described in Supplementary Table 12.

352

353 Genome-wide association scan of genotyped rare nonsynonymous genetic variants

354 Genetic variants were genotyped in UK Biobank using the Affymetrix UK BiLEVE or the Affymetrix UK 355 Biobank Axiom arrays (57). Genotyping underwent quality control procedures including (a) routine quality 356 checks carried out during the process of sample retrieval, DNA extraction, and genotype calling; (b) checks and filters for genotype batch effects, plate effects, departures from Hardy Weinberg equilibrium, sex 357 358 effects, array effects, and discordance across control replicates; and (c) individual and genetic variant call 359 rate filters as previously described (57). We further excluded genetic variants with a genotype call rate 360 below 95% and variants that were (i) not rare (0.1%≤MAF≤0.5%) or (ii) not non-synonymous or (iii) had poor correlation (r<0.9) or rare allele concordance (<0.9) when compared to the whole exome sequence 361 362 data (Supplementary Table 2). Genomic annotations were performed using the ANNOVAR software (58). 363 The coordinates of genotyped rare variants were lifted over from GRCh37 to GRCh38 using liftOver and 364 all reported positions in this study are in GRCh38. A total of 13,181 genetic variants in 7,481 genes were 365 available for analysis. Genome-wide association analyses were performed using the BOLT-LMM software 366 (59) in 450,562 participants of European Ancestry defined using a K-means clustering approach applied to 367 the first four principal components calculated from genome-wide SNP genotypes.

Sex-specific genome-wide association analyses were performed using the BOLT-LMM software (59) in
 206,082 men and 244,478 women of European ancestry from UK Biobank. Evidence for sex differences at

the variants identified in the sex combined analysis were formally tested in unrelated individuals using a

It is made available under a CC-BY-NC-ND 4.0 International license .

linear regression model including an interaction term between the genetic variant and sex using the samecovariates used in the discovery analysis.

373

374 Conditional analyses and fine-mapping

375 At each associated genomic region, we conducted systematic analyses of the genomic context of 376 associations. Our goal was to establish whether or not the identified rare nonsynonymous variants are likely 377 to be the causal variants for the association with WHR_{adjBMI}. At each region 1 Mb either side of the 378 nonsynonymous genetic variants associated with WHR_{adjBMI}, we conducted both approximate and formal 379 conditional analyses. We considered the association of all genetic variants in the regions regardless of 380 functional annotation or allele frequency using directly-genotyped and imputed data (imputed using the 381 Haplotype Reference Consortium (HRC) and UK10K haplotype resource). First, approximate conditional 382 analyses were conducted on summary-level estimates using GCTA (60, 61) to identify sets of conditionallyindependent index genetic variants ($p < 5 \times 10^{-8}$). Individual-level genotypes for the conditionally-383 384 independent variants identified in this first step were then extracted in 350,721 unrelated European ancestry 385 participants of UK Biobank and their independent association was confirmed in multivariable linear 386 regression models including all variants put forward from approximate analyses. Then, at each region, we 387 statistically decomposed the identified index signals by conditioning on the other conditionally-independent 388 index variants. We then performed Bayesian fine-mapping (62) to estimate the posterior probability of 389 association for each variant (PPA, where 0% indicates that the variant is not causal and 100% indicates the 390 highest possible posterior probability that the variant is causal) and define the 99% credible set at that signal 391 (i.e. a set of variants in a genomic window that accounts for 99% of the PPA at that association signal). To 392 generate credible sets, the association results at each locus were converted to Bayes factors (BF) for each 393 variant within the locus boundary. The posterior probability that a variant-j was causal was defined by:

394
$$\Phi_j = \frac{BF_j}{\sum_k BF_k}$$

395

where, BF_j denotes the BF for the j_{th} variant, and the denominator is the sum of BF_s for all included variants at that signal. A 99% credible set of variants was created by ranking the posterior probabilities from highest to lowest and summing them until the cumulative posterior probability exceeded 0.99 (i.e. 99%).

It is made available under a CC-BY-NC-ND 4.0 International license .

399

400 UK Biobank exome-sequence data processing and QC

Whole exome sequencing (WES) data of 200,643 UK Biobank participants made available in October 2020 401 402 were downloaded in VCF and PLINK formats. The details of the UK Biobank WES data processing are 403 provided in detail elsewhere (63, 64). Further data processing and quality control has been described 404 previously (65). In brief, we did not apply additional QC based on QUAL (variant site-level quality score, Phred scale) or AO measures (variant site-level allele quality score reflecting evidence for each alternate 405 406 allele, Phred scale). Site-level filtering was applied for targeted biallelic calls if the AB ratio (no. of alternate allele reads/total depth) was ≤0.25 or ≥0.8. Variant-level QC filters were applied if any of the variants had 407 (i) genotype missingness > 5%, (ii) maximum read depth (DP) of less than 10 across samples or (iii) had 408 409 GQ less than 20 for over 20% of the calls. After applying these filters, 7.3% of the variants were flagged as poor quality and not taken forward for further analysis. 410

411

412 Variant annotation and definition of gene burden sets

We annotated variants released in UK Biobank 200K whole exome sequencing VCF files in build hg38, 413 using the Variant Effect Predictor (VEP) tool release 99 provided by Ensembl (66). In addition to default 414 VEP features such as the consequence and impact of the variant, overlapping gene, position at cDNA and 415 protein level and codon and amino acid change, if applicable, we have used the following plugins for 416 417 annotation: (i) SIFT (67), which predicts whether an amino acid substitution affects protein function based on sequence homology and the physical properties of amino acid, (ii) Polyphen-2 (25), which predicts 418 419 possible impact of an amino acid substitution on the structure and function of a human protein, (iii) CADD 420 (27) which provides deleteriousness prediction scores for all variants based on diverse genomic features 421 and (iv) LOFTEE (68) which provides loss of function prediction for variants. We annotated each variant 422 using the most severe consequence across overlapping transcripts in Ensembl. We defined loss of function 423 variants as those with 'high' impact predict by VEP. This includes frameshift variants, transcript ablating 424 or transcript amplifying variants, splice acceptor or splice donor variants, stop lost, start gained or stop 425 gained variants. 'Moderate impact' variants include missense variants, in-frame deletion or insertions, missense variants and protein altering variants. 426

427

428

429 Gene-based association testing

It is made available under a CC-BY-NC-ND 4.0 International license .

430 In our discovery stage, we used the method STAAR (variant-Set Test for Association using Annotation 431 infoRmation), which is a computationally scalable method for very large whole-exome sequence (WES) 432 and whole-exome sequence (WGS) studies and large-scale biobanks. STAAR uses a Generalized Linear Mixed Model (GLMM) framework that includes linear and logistic mixed models and can also account for 433 434 both relatedness and population structure for both quantitative and dichotomous traits (69). In our analysis, we used the genotype dosage matrix as the genotype input and covariates including age at first check (age), 435 436 age², sex, genotyping array, top ten genetically derived principal components (PC1-PC10) generated from 437 the SNP array data, exome sequencing batch and the sparse GRM. For rank-based inverse normal 438 transformed WHR_{adiBMI}, we also added BMI as a covariate. We excluded the samples from our analysis if 439 they did not pass UK Biobank quality control parameters, were non-European ancestry or if they withdrew 440 consent from the study (n=184,246) (65).

441 We ran STAAR with its default options without additional functional annotations. For each gene, with at least two variants with MAF $\leq 0.5\%$, we conducted gene-based association analysis for the following three 442 443 variant categories: rare variants predicted by VEP to be a) loss of function (pLoF; i.e. high impact), b) 444 missense (Moderate; i.e. moderate impact) or c) both (pLoF+Moderate). For each variant clustering of a 445 gene, STAAR will provide p-values for several collapsing burden tests including SKAT (sequence kernel 446 association test), Burden test, and ACAT-V (set-based aggregated Cauchy association test). In addition, the 447 output of STAAR also includes the omnibus p-value (STAAR-O) by using the combined Cauchy 448 association test to aggregate the association across the different tests.

- After identifying the genes with STAAR-O p-value over the threshold for exome-wide significance ($p<2.53\times10^{-6}$), we applied more stringent QC filters on the genotype calls of the included variants. We set to missing genotype calls which did not meet the following QC criteria: 1. Genotype Quality (GQ) ≥ 20 for heterozygous variants; 2. Depth (DP) ≥ 7 for SNVs and DP ≥ 10 for InDels; 3. A binomial test on allelic balance using the Allelic Depth (AD) FORMAT field for heterozygous variants with $p\ge1x10^{-3}$. We then repeated the STAAR analysis using the filtered genotype dosage matrix.
- To examine the extent to which the gene-based association is driven by single variants, we conducted a sensitivity leave-one-out analysis for each significant gene ($p < 2.53 \times 10^{-6}$), testing the significance of the gene-based association after excluding each variant.
- 458

459 Secondary association testing

We created dichotomous dummy variables using the filtered genotype dosage matrix for each identified gene, where samples with one or more rare alleles were set as "1" and the samples without rare alleles were

It is made available under a CC-BY-NC-ND 4.0 International license .

462 set as "0" for different variant clustering settings of each gene. Then we combined these dummy variables 463 into a single file and transformed it to BGEN format, which was used as the genotype input for association 464 testing using a linear mixed model implemented in BOLT-LMM to account for cryptic population structure and relatedness (59). The GRM in BOLT-LMM was generated from the autosomal genetic variants that 465 were common (MAF > 1%), passed quality control in all 106 batches, and were present on both genotyping 466 arrays (65). Covariates included age, sex, and PC1-PC10, genotyping chip and exome sequencing batch. 467 468 For rank-based inverse normal transformed WHR_{adjBMI}, covariates also included BMI. We excluded the 469 same group of samples as we did for STAAR analyses.

- 470 To test for heterogeneity of effect sizes between men and women for significant genes identified in the
- gene-based analyses, we used a Z-test to compare effect size estimates for each gene calculated in the sex-
- 472 specific analyses.
- 473

474 **Phenotypic associations**

The gene-based phenotypic associations using the same STAAR and BOLT-LMM pipelines for the following continuous phenotypes: BMI, BIA-derived gynoid fat, BIA-derived leg fat, BIA-derived android fat, BIA-derived trunk fat, BIA-derived arm fat, triglyceride levels, HDL cholesterol, LDL cholesterol, HbA1c levels (see Supplementary Table 12 for phenotype details). Body fat compartments were predicted using bioimpedance measurements in UK Biobank. The details for the prediction of body fat compartments in UK Biobank are described elsewhere (16).

481 We have also investigated gene-based phenotypic associations for binary disease outcomes: type 2 diabetes 482 and cardiovascular heart disease. As BOLT-LMM is based on the linear mixed model which cannot give 483 an accurate effect estimate for binary variables, we have also applied a generalized linear model (GLM) to 484 estimate the Odd Ratio (OR) for binary phenotypes. We also looked up these binary outcomes in other 485 resources such as the AstraZeneca PheWAS Portal (https://azphewas.com/, accessed on 02/09/2021) (14) 486 and the Type 2 Diabetes Knowledge Portal (T2DKP; https://t2d.hugeamp.org/, accessed on 02/09/2021). 487 The AstraZeneca PheWAS Portal also uses UK Biobank as their primary resource, but have access to a larger dataset of 281.104 exomes. We looked up results for T2D (N cases = 1.671: N controls = 160.949) 488 489 and chronic ischaemic heart disease (defined by ICD-10 code I25; N cases =24,147, N controls = 176,170). 490 In the T2DKP, we also looked up results for T2D (N=43,125).

491

492

It is made available under a CC-BY-NC-ND 4.0 International license .

493 ACVR1C dual-luciferase assay

HEK293 cells were seeded at a density of 150,000 cells per well in 24-well tissue culture plates pre-treated
with poly-D-lysine. On the following day, medium was replaced with Opti-MEM I Reduced Serum medium
and a total of 550 ng of plasmid DNA; this included different pcDNA3.1 based ACVR1C constructs listed
in the table below, as well as constructs encoding receptor components (ACVR-IIB and CRIPTO) along
with firefly (consisting of the SMAD binding elements) and *Renilla* (control) luciferase reporter plasmids.
Lipofectamine 3000 Reagent was used for the transfection according to the manufacturer's protocol. OptiMEM I Reduced Serum medium was then replaced with DMEM growth medium 6 hours post transfection.

501

pcDNA3.1 construct	Receptor components
WT	ACVR-IIB, CRIPTO, pGL4.48[<i>luc2P</i> /SBE/Hygro], pRL-SV40
I195T	ACVR-IIB, CRIPTO, pGL4.48[<i>luc2P</i> /SBE/Hygro], pRL-SV40
K222R	ACVR-IIB, CRIPTO, pGL4.48[<i>luc2P</i> /SBE/Hygro], pRL-SV40
T194D	ACVR-IIB, CRIPTO, pGL4.48[<i>luc2P</i> /SBE/Hygro], pRL-SV40
EV (empty vector)	ACVR-IIB, CRIPTO, pGL4.48[<i>luc2P</i> /SBE/Hygro], pRL-SV40

502

503 The dual-luciferase reporter assay was performed according to the manufacturer's protocol (Promega, USA). Cells were washed once with DPBS, followed by an active lysis procedure. Briefly, 125 µl of passive 504 505 lysis buffer was added in each well and the cells were subjected to one cycle of a freeze-thaw process. Cell lysates were cleared of cell debris by centrifugation at $21,130 \times g$ for one minute. The assay was conducted 506 507 in a 96-well plate format. In each assay, 20 µl of cleared supernatant was pre-dispensed, followed by sequential measurement of firefly and Renilla luciferase using a Tecan Spark 10M plate reader (Tecan, 508 509 Switzerland). Firefly luciferase activity was normalised for *Renilla* luciferase activity, and then further 510 normalised with values from non-stimulated cells transfected with empty pcDNA3.1 vector (EV). We also 511 studied a constitutively active (ACVR1C p.T194D) mutant and a kinase dead (ACVR1C p.K222R) mutant 512 for comparison (70, 71). The experiment was repeated with fresh transfections on three separate occasions.

513

514

It is made available under a CC-BY-NC-ND 4.0 International license .

515 **REFERENCES**

516 1. Lotta LA, Wittemans LBL, Zuber V, Stewart ID, Sharp SJ, Luan J, et al. Association of Genetic

517 Variants Related to Gluteofemoral vs Abdominal Fat Distribution With Type 2 Diabetes, Coronary Disease,
518 and Cardiovascular Risk Factors. JAMA. 2018;320(24):2553-63.

Shungin D, Winkler TW, Croteau-Chonka DC, Ferreira T, Locke AE, Mägi R, et al. New genetic
 loci link adipose and insulin biology to body fat distribution. Nature. 2015;518(7538):187-96.

521 3. Pulit SL, Stoneman C, Morris AP, Wood AR, Glastonbury CA, Tyrrell J, et al. Meta-analysis of
522 genome-wide association studies for body fat distribution in 694 649 individuals of European ancestry.

523 Hum Mol Genet. 2019;28(1):166-74.

4. Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, Handsaker RE, et al. An integrated
map of genetic variation from 1,092 human genomes. Nature. 2012;491(7422):56-65.

5. Claussnitzer M, Cho JH, Collins R, Cox NJ, Dermitzakis ET, Hurles ME, et al. A brief history of
human disease genetics. Nature. 2020;577(7789):179-89.

528 6. Wang Q, Dhindsa RS, Carss K, Harper A, Nag A, Tachmazidou I, et al. Surveying the contribution
529 of rare variants to the genetic architecture of human disease through exome sequencing of 177,882 UK
530 Biobank participants. bioRxiv. 2020;2020.12.13.422582.

7. Raychaudhuri S. Mapping rare and common causal alleles for complex human diseases. Cell.
2011;147(1):57-69.

McCarthy S, Das S, Kretzschmar W, Delaneau O, Wood AR, Teumer A, et al. A reference panel
of 64,976 haplotypes for genotype imputation. Nat Genet. 2016;48(10):1279-83.

Justice AE, Karaderi T, Highland HM, Young KL, Graff M, Lu Y, et al. Protein-coding variants
implicate novel genes related to lipid homeostasis contributing to body-fat distribution. Nat Genet.
2019;51(3):452-69.

538 10. Akbari P, Gilani A, Sosina O, Kosmicki JA, Khrimian L, Fang YY, et al. Sequencing of 640,000
539 exomes identifies *GPR75* variants associated with protection from obesity. Science. 2021;373(6550).

540 11. Dewey FE, Murray MF, Overton JD, Habegger L, Leader JB, Fetterolf SN, et al. Distribution and
541 clinical impact of functional variants in 50,726 whole-exome sequences from the DiscovEHR study.
542 Science. 2016;354(6319).

543 12. Van Hout CV, Tachmazidou I, Backman JD, Hoffman JD, Liu D, Pandey AK, et al. Exome
544 sequencing and characterization of 49,960 individuals in the UK Biobank. Nature. 2020;586(7831):749-56.

Park J, Lucas AM, Zhang X, Chaudhary K, Cho JH, Nadkarni G, et al. Exome-wide evaluation of
rare coding variants using electronic health records identifies new gene-phenotype associations. Nat Med.
2021;27(1):66-72.

It is made available under a CC-BY-NC-ND 4.0 International license .

- 548 14. Wang Q, Dhindsa RS, Carss K, Harper AR, Nag A, Tachmazidou I, et al. Rare variant contribution
 549 to human disease in 281,104 UK Biobank exomes. Nature. 2021.
- 550 15. Granneman JG, Moore HP, Krishnamoorthy R, Rathod M. Perilipin controls lipolysis by regulating
- the interactions of AB-hydrolase containing 5 (Abhd5) and adipose triglyceride lipase (Atgl). J Biol Chem.
- 552 2009;284(50):34538-44.
- Powell R, De Lucia Rolfe E, Day FR, Perry JRB, Griffin SJ, Forouhi NG, et al. Development and
 validation of total and regional body composition prediction equations from anthropometry and single
 frequency segmental bioelectrical impedance with DEXA. medRxiv. 2020;2020.12.16.20248330.
- McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven G. Use of metabolic markers to
 identify overweight individuals who are insulin resistant. Ann Intern Med. 2003;139(10):802-9.
- 558 18. Freeman AM, Pennings N. Insulin Resistance. StatPearls. Treasure Island (FL): StatPearls559 Publishing
- 560 Copyright © 2021, StatPearls Publishing LLC.; 2021.
- 561 19. Zhu Z, Guo Y, Shi H, Liu CL, Panganiban RA, Chung W, et al. Shared genetic and experimental
 562 links between obesity-related traits and asthma subtypes in UK Biobank. J Allergy Clin Immunol.
 563 2020;145(2):537-49.
- Semple RK, Savage DB, Cochran EK, Gorden P, O'Rahilly S. Genetic syndromes of severe insulin
 resistance. Endocr Rev. 2011;32(4):498-514.
- Emdin CA, Khera AV, Aragam K, Haas M, Chaffin M, Klarin D, et al. DNA Sequence Variation
 in *ACVR1C* Encoding the Activin Receptor-Like Kinase 7 Influences Body Fat Distribution and Protects
- 568 Against Type 2 Diabetes. Diabetes. 2019;68(1):226-34.
- Jagadeesh KA, Wenger AM, Berger MJ, Guturu H, Stenson PD, Cooper DN, et al. M-CAP
 eliminates a majority of variants of uncertain significance in clinical exomes at high sensitivity. Nat Genet.
 2016;48(12):1581-6.
- 572 23. Ioannidis NM, Rothstein JH, Pejaver V, Middha S, McDonnell SK, Baheti S, et al. REVEL: An
 573 Ensemble Method for Predicting the Pathogenicity of Rare Missense Variants. Am J Hum Genet.
 574 2016;99(4):877-85.
- 575 24. Ng PC, Henikoff S. SIFT: Predicting amino acid changes that affect protein function. Nucleic Acids
 576 Res. 2003;31(13):3812-4.
- 577 25. Adzhubei I, Jordan DM, Sunyaev SR. Predicting functional effect of human missense mutations
 578 using PolyPhen-2. Curr Protoc Hum Genet. 2013;Chapter 7:Unit7.20.
- 579 26. Choi Y, Chan AP. PROVEAN web server: a tool to predict the functional effect of amino acid
- substitutions and indels. Bioinformatics. 2015;31(16):2745-7.

It is made available under a CC-BY-NC-ND 4.0 International license .

- 581 27. Rentzsch P, Witten D, Cooper GM, Shendure J, Kircher M. CADD: predicting the deleteriousness
 582 of variants throughout the human genome. Nucleic Acids Res. 2019;47(D1):D886-D94.
- 583 28. Sinnott-Armstrong N, Tanigawa Y, Amar D, Mars N, Benner C, Aguirre M, et al. Genetics of 35
 584 blood and urine biomarkers in the UK Biobank. Nat Genet. 2021;53(2):185-94.
- 585 29. Klarin D, Damrauer SM, Cho K, Sun YV, Teslovich TM, Honerlaw J, et al. Genetics of blood
 586 lipids among ~300,000 multi-ethnic participants of the Million Veteran Program. Nat Genet.
 587 2018;50(11):1514-23.
- 588 30. Vuckovic D, Bao EL, Akbari P, Lareau CA, Mousas A, Jiang T, et al. The Polygenic and
 589 Monogenic Basis of Blood Traits and Diseases. Cell. 2020;182(5):1214-31.e11.
- 590 31. Emdin CA, Khera AV, Chaffin M, Klarin D, Natarajan P, Aragam K, et al. Analysis of predicted
 591 loss-of-function variants in UK Biobank identifies variants protective for disease. Nat Commun.
 592 2018;9(1):1613.
- 593 32. Pischon T, Boeing H, Hoffmann K, Bergmann M, Schulze MB, Overvad K, et al. General and
 594 abdominal adiposity and risk of death in Europe. N Engl J Med. 2008;359(20):2105-20.
- Wang Y, Rimm EB, Stampfer MJ, Willett WC, Hu FB. Comparison of abdominal adiposity and
 overall obesity in predicting risk of type 2 diabetes among men. Am J Clin Nutr. 2005;81(3):555-63.
- 597 34. Canoy D. Distribution of body fat and risk of coronary heart disease in men and women. Curr Opin
 598 Cardiol. 2008;23(6):591-8.
- 599 35. Mason C, Craig CL, Katzmarzyk PT. Influence of central and extremity circumferences on all600 cause mortality in men and women. Obesity (Silver Spring). 2008;16(12):2690-5.
- Bogardus C, Lillioja S, Mott DM, Hollenbeck C, Reaven G. Relationship between degree of obesity
 and in vivo insulin action in man. Am J Physiol. 1985;248(3 Pt 1):E286-91.
- For a straight of the straight of the
- 8. Rose KM, Newman B, Mayer-Davis EJ, Selby JV. Genetic and behavioral determinants of waisthip ratio and waist circumference in women twins. Obes Res. 1998;6(6):383-92.
- Lim K, Haider A, Adams C, Sleigh A, Savage DB. Lipodistrophy: a paradigm for understanding
 the consequences of "overloading" adipose tissue. Physiol Rev. 2021;101(3):907-93.
- 610 40. Emdin CA, Khera AV, Natarajan P, Klarin D, Zekavat SM, Hsiao AJ, et al. Genetic Association of
 611 Waist-to-Hip Ratio With Cardiometabolic Traits, Type 2 Diabetes, and Coronary Heart Disease. JAMA.
 612 2017;317(6):626-34.
- 41. Locke AE, Kahali B, Berndt SI, Justice AE, Pers TH, Day FR, et al. Genetic studies of body mass
 index yield new insights for obesity biology. Nature. 2015;518(7538):197-206.

It is made available under a CC-BY-NC-ND 4.0 International license .

Fischer JP, Els-Heindl S, Beck-Sickinger AG. Adrenomedullin - Current perspective on a peptide
hormone with significant therapeutic potential. Peptides. 2020;131:170347.

- 617 43. Erratum to: "Altered Expression of Adrenomedullin 2 and its Receptor in the Adipose Tissue of618 Obese Patients". J Clin Endocrinol Metab. 2020;105(12).
- 44. Sztalryd C, Brasaemle DL. The perilipin family of lipid droplet proteins: Gatekeepers of
 intracellular lipolysis. Biochim Biophys Acta Mol Cell Biol Lipids. 2017;1862(10 Pt B):1221-32.
- 45. Degerman E, Ahmad F, Chung YW, Guirguis E, Omar B, Stenson L, et al. From PDE3B to the
 regulation of energy homeostasis. Curr Opin Pharmacol. 2011;11(6):676-82.
- 46. DiPilato LM, Ahmad F, Harms M, Seale P, Manganiello V, Birnbaum MJ. The Role of PDE3B
 Phosphorylation in the Inhibition of Lipolysis by Insulin. Mol Cell Biol. 2015;35(16):2752-60.
- 47. Yogosawa S, Mizutani S, Ogawa Y, Izumi T. Activin receptor-like kinase 7 suppresses lipolysis to
 accumulate fat in obesity through downregulation of peroxisome proliferator-activated receptor γ and
 C/EBPα. Diabetes. 2013;62(1):115-23.
- 48. Ibáñez CF. Regulation of metabolic homeostasis by the TGF-β superfamily receptor ALK7. FEBS
 J. 2021.
- Guo T, Marmol P, Moliner A, Björnholm M, Zhang C, Shokat KM, et al. Adipocyte ALK7 links
 nutrient overload to catecholamine resistance in obesity. Elife. 2014;3:e03245.
- 50. Laver TW, Patel KA, Colclough K, Curran J, Dale J, Davis N, et al. PLIN1 Haploinsufficiency Is
 Not Associated With Lipodystrophy. J Clin Endocrinol Metab. 2018;103(9):3225-30.
- 51. Jéru I, Vantyghem MC, Bismuth E, Cervera P, Barraud S, Auclair M, et al. Diagnostic Challenge
 in PLIN1-Associated Familial Partial Lipodystrophy. J Clin Endocrinol Metab. 2019;104(12):6025-32.
- 636 52. Gandotra S, Le Dour C, Bottomley W, Cervera P, Giral P, Reznik Y, et al. Perilipin deficiency and
 637 autosomal dominant partial lipodystrophy. N Engl J Med. 2011;364(8):740-8.
- 638 53. Chen W, Chang B, Wu X, Li L, Sleeman M, Chan L. Inactivation of Plin4 downregulates Plin5
 639 and reduces cardiac lipid accumulation in mice. Am J Physiol Endocrinol Metab. 2013;304(7):E770-9.
- 54. Lagou V, Mägi R, Hottenga JJ, Grallert H, Perry JRB, Bouatia-Naji N, et al. Sex-dimorphic genetic
 effects and novel loci for fasting glucose and insulin variability. Nat Commun. 2021;12(1):24.
- 642 55. Garg A. Gender differences in the prevalence of metabolic complications in familial partial
 643 lipodystrophy (Dunnigan variety). J Clin Endocrinol Metab. 2000;85(5):1776-82.
- 644 56. Mann JP, Savage DB. What lipodystrophies teach us about the metabolic syndrome. J Clin Invest.
 645 2019;129(10):4009-21.
- 57. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK Biobank resource
 with deep phenotyping and genomic data. Nature. 2018;562(7726):203-9.

It is made available under a CC-BY-NC-ND 4.0 International license .

- 648 58. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-
- throughput sequencing data. Nucleic Acids Res. 2010;38(16):e164.
- 59. Loh PR, Tucker G, Bulik-Sullivan BK, Vilhjálmsson BJ, Finucane HK, Salem RM, et al. Efficient
- Bayesian mixed-model analysis increases association power in large cohorts. Nat Genet. 2015;47(3):284-
- **652** 90.
- 653 60. Yang J, Lee SH, Goddard ME, Visscher PM. GCTA: a tool for genome-wide complex trait analysis.
- 654 Am J Hum Genet. 2011;88(1):76-82.
- 655 61. Yang J, Ferreira T, Morris AP, Medland SE, Madden PA, Heath AC, et al. Conditional and joint
- multiple-SNP analysis of GWAS summary statistics identifies additional variants influencing complex
 traits. Nat Genet. 2012;44(4):369-75, S1-3.
- 658 62. Maller JB, McVean G, Byrnes J, Vukcevic D, Palin K, Su Z, et al. Bayesian refinement of 659 association signals for 14 loci in 3 common diseases. Nat Genet. 2012;44(12):1294-301.
- 660 63. Szustakowski JD, Balasubramanian S, Kvikstad E, Khalid S, Bronson PG, Sasson A, et al.
 661 Advancing human genetics research and drug discovery through exome sequencing of the UK Biobank.
 662 Nu C (2021 52/7) 042 9
- 662 Nat Genet. 2021;53(7):942-8.
- 663 64. Yun T, Li H, Chang PC, Lin MF, Carroll A, McLean CY. Accurate, scalable cohort variant calls
 664 using DeepVariant and GLnexus. Bioinformatics. 2021.
- 65. Zhao Y, Stankovic S, Koprulu M, Wheeler E, Day FR, Lango Allen H, et al. GIGYF1 loss of function is associated with clonal mosaicism and adverse metabolic health. Nat Commun. 2021;12(1):4178.
- 667 66. McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GR, Thormann A, et al. The Ensembl Variant Effect
 668 Predictor. Genome Biol. 2016;17(1):122.
- 669 67. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein
 670 function using the SIFT algorithm. Nat Protoc. 2009;4(7):1073-81.
- 671 68. Karczewski K. Loftee (Loss-of-Function Transcript Effect Estimator) 2015.
- 672 69. Li X, Li Z, Zhou H, Gaynor SM, Liu Y, Chen H, et al. Dynamic incorporation of multiple in silico
 673 functional annotations empowers rare variant association analysis of large whole-genome sequencing
 674 studies at scale. Nat Genet. 2020;52(9):969-83.
- 675 70. Bondestam J, Huotari MA, Morén A, Ustinov J, Kaivo-Oja N, Kallio J, et al. cDNA cloning,
 676 expression studies and chromosome mapping of human type I serine/threonine kinase receptor ALK7
 677 (ACVR1C). Cytogenet Cell Genet. 2001;95(3-4):157-62.
- 678 71. Wieser R, Wrana JL, Massagué J. GS domain mutations that constitutively activate T beta R-I, the
 679 downstream signaling component in the TGF-beta receptor complex. EMBO J. 1995;14(10):2199-208.
- 680
- 681

It is made available under a CC-BY-NC-ND 4.0 International license .

682 Acknowledgements

683

This research has been conducted using the UK Biobank resource. Access to the UK Biobank genotype and 684 phenotype data is open to all approved health researchers (http://www.ukbiobank.ac.uk/). This study was 685 funded by the United Kingdom's Medical Research Council through grants MC_UU_12015/1, 686 MC PC 13046, MC PC 13048 and MR/L00002/1. This work was supported by the MRC Metabolic 687 688 Diseases Unit (MC_UU_12012/5) and the Cambridge NIHR Biomedical Research Centre and EU/EFPIA 689 Innovative Medicines Initiative Joint Undertaking (EMIF grant: 115372). R.K.S, D.B.S. and S.O'R. are 690 supported by the Wellcome Trust (WT 210752, WT 219417 and WT 214274 respectively) the MRC Metabolic Disease Unit, the National Institute for Health Research (NIHR) Cambridge Biomedical 691 692 Research Centre and the NIHR Rare Disease Translational Research Collaboration. K.S.S. is supported by 693 MRC Project Grant L01999X/1. Some computation was enabled through access granted to K.S.S. to the 694 MRC eMedLab Medical Bioinformatics infrastructure, supported by the Medical Research Council (grant 695 number MR/L016311/1). M.McC. is a Wellcome Senior Investigator supported by Wellcome grants 696 098381, 090532, 106130, 203141. M.McC. declares that the views expressed in this article are those of the 697 authors and not necessarily those of the NHS, the NIHR, or the Department of Health; he has served on advisory panels for Pfizer, Novo Nordisk and Zoe Global, has received honoraria from Merck, Pfizer, Novo 698 699 Nordisk and Eli Lilly, and research funding from Abbvie, Astra Zeneca, Boehringer Ingelheim, Eli Lilly, 700 Janssen, Merck, Novo Nordisk, Pfizer, Roche, Sanofi Aventis, Servier, and Takeda. M.K. is supported by 701 the Gates Cambridge Trust. The authors gratefully acknowledge the help of the MRC Epidemiology Unit 702 Support Teams, including Field, Laboratory and Data Management Teams.

703

704 Competing interests

M.McM. is an employee of Genentech, and a holder of Roche stock. D.M.E.L. is currently an employee of
Enhanc3D Genomics Ltd. N.B. is an employee of GlaxoSmithKline Plc. (GSK). R.A.S. is an employee
and shareholder of GlaxoSmithKline Plc. (GSK). C.A.G. is an employee of Benevolent AI. L.A.L. is an
employee of Regeneron Genetics Center and receives salary, stocks and stock options from Regeneron
Pharmaceuticals Inc.

710

711 Author contributions

Data collection and analysis: M.K., Y.Z., E.W., L.D., N.R., S.P., M.V.S., C.G., I.D.S, F.R.D, J.L., N.B.,
L.B.L.W., N.D.K., V.S.,

514 Study supervision: D.M.E.L., I.B., M.I.McM., R.A.S., K.S.S., N.J.W., R.K.S., L.A.L, J.R.B.P., S.O'R.,

715 C.L., D.B.S.

It is made available under a CC-BY-NC-ND 4.0 International license .

716

717 Data availability

- 718 This research has been conducted using the UK Biobank resource (application no. 44448 and 9905).
- 719 Access to the UK Biobank genotype and phenotype data is open to all approved health researchers
- 720 (http://www.ukbiobank.ac.uk/).